Skip to main navigation Skip to search Skip to main content

Brain-derived extracellular vesicle (BDEV) abundance and BDEV protein associations with clinical phenotypes and treatment response in untreated first-episode psychosis

Research output: Contribution to journal › Article › peer-review

Abstract

Reliable biomarkers that capture central nervous system (CNS) processes during the earliest stages of psychosis are critically needed to improve early treatment and response monitoring. Brain-derived extracellular vesicles (BDEVs) that traverse the blood–brain barrier (BBB) can be isolated from peripheral blood, thereby offering a novel and minimally invasive approach to quantify CNS molecular biomarkers. We hypothesized that BDEV abundance and BDEV neuroinflammatory and neurotrophic protein cargo would differ between individuals with first-episode psychosis (FEP) and healthy controls (HCs), reflecting altered neuroinflammatory signalling and extracellular biology associated with psychosis and clinical outcomes. In a cohort of untreated individuals with FEP (n = 57) and HCs (n = 28), BDEVs were isolated from serum. Luminex assays quantified concentrations of brain-derived neurotrophic factor (BDNF), S100 calcium-binding protein B (S100B), and C-reactive protein (CRP) in BDEVs and serum. A subset of FEP participants (n = 34) subsequently completed four weeks of antipsychotic treatment. Group differences in BDEV characteristics and protein measures, as well as their associations with case-control status, baseline symptom severtity, and four-week symptom change, were examined. FEP participants showed a trend toward higher BDEV concentration than HCs (median 14.0 × 108 versus 10.2 × 108 particles/mL, p = 0.052), and higher baseline BDEV concentrations were significantly associated with more severe pretreatment symptoms (β = 4.09 × 10−10, p = 0.003) and greater symptom improvement after four-week antipsychotic treatment (β = 3.29 × 10−10, p = 0.029). Within BDEVs, BDNF (β = −1.05; p = 0.0018) and CRP (β = −0.84; p = 0.002) were significantly reduced in FEP vs HC, with a trend toward lower S100B level (β = −0.57; p = 0.061). In contrast, serum protein levels showed no case-control differences and did not correlate with corresponding BDEV protein levels. Lower baseline BDEV BDNF, S100B, and CRP were associated with greater therapeutic response among males. BDEVs offer a minimally invasive window into CNS-enriched biology in early psychosis. BDEV abundance and neuroinflammatory and neurotrophic cargo concentrations show associations with illness severity and sex-specific treatment response not detectable in serum, supporting their potential as biomarkers for early pathophysiology and treatment response in FEP.

Original languageEnglish (US)
Article number106912
JournalBrain, Behavior, and Immunity
Volume138
DOIs
StatePublished - Nov 2026

Bibliographical note

Publisher Copyright:
Copyright © 2026. Published by Elsevier Inc.

Keywords

  • Antipsychotic treatment
  • BDNF
  • Brain-derived extracellular vesicles
  • CRP
  • Exosomes
  • First-episode psychosis
  • Neuroinflammation
  • Psychotic symptoms
  • S100B

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Brain-derived extracellular vesicle (BDEV) abundance and BDEV protein associations with clinical phenotypes and treatment response in untreated first-episode psychosis'. Together they form a unique fingerprint.

Cite this